Trial
NCT05123586
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Systemic Lupus Erythematosus
Intervention
LY3361237
Why stopped
Study terminated due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-20